A novel approach for delivery of enzyme drugs: Preliminary demonstration of feasibility and utility in vitro

International Journal of Pharmaceutics

Volumn 202, Issue 1-2, 2000, Pages 11-20

  Liang, Jun F ^a   Li, Yong T ^a   Yang, Victor C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Enzyme drugs; Heparin; Pro drug feature; Protamine; Streptokinase; Triggered release feature

Indexed keywords

ENZYME; HEPARIN; PRODRUG; PROTAMINE; STREPTOKINASE; TRYPSIN;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG TARGETING; IN VITRO STUDY; PRIORITY JOURNAL;

AZURE STAINS; DRUG DELIVERY SYSTEMS; ENZYMES; FEASIBILITY STUDIES; FIBRINOLYTIC AGENTS; HEPARIN; PRODRUGS; STREPTOKINASE; TRYPSIN;

EID: 0034691810     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00414-2     Document Type: Article

References (19)

1. Ahlke E., Nowak-Gottl U., Schulze-Westhoff P. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br. J. Haematol. 96:1997;675-681.
2. Bode C., Runge M.S., Branscomb E.E., Newell J.B., Matsueda G.R., Haber E. Antibody-directed fibrinolysis. J. Biol. Chem. 264:1989;944-948.
3. Byun Y., Singh V.K., Yang V.C. Low molecular weight protamine: a potential non-toxic heparin antagonist. Thromb. Res. 94:1999;53-61.
4. Falabella A.F., Carson P., Eaglstein W.H., Falanga V.J. The safety and efficacy of a proteolytic ointment in the treatment of chronic ulcers of the lower extremity. Am. Acad. Dermatol. 39:1998;737-740.
5. Hershfield M.S., Chaffee S., Koro-Johnson L., Smith M.A., Short S.A. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. USA. 88:1991;7185-7189.
6. Jaques L.B. Protamine: antagonist to heparin. Can. Med. Assoc. J. 237:1973;879-881.
7. Jaques L.B. Heparin: anionic polyelectrolyte drugs. Pharmacol. Rev. 31:1980;99-166.
8. Lijnen H.R., Collen D. Strategies for the improvement of thrombolytic agents. Thromb. Haemost. 66:1991;88-110.
9. Ma S.C., Meyerhoff M.E., Yang V.C. Electrochemical sensor for heparin: further characterization and bioanalytical applications. Anal. Chem. 65:1993;2078-2084.
10. Majerus P.W., Broze G.J. Jr, Miletich J.P., Tollefsen D.M. Anticoagulant, thrombolytic, and antiplatelet drugs. Gilman A.G., Goodman L.S. The Pharmacological Basis of Therapeutics. 9th ed. 1995;1341-1360 McGraw-Hill, New York.
11. Makepeace A.R. Enzymatic debridement of burns. Burns Incl. Therm. Inj. 9:1983;153-157.
12. Mikolajczyk S.D., Meyer D.L., Fagnani R., Hagan M.S., Law K.L., Starling J.J. Dextran modification of a Fab'-beta-lactamase conjugate modulated by variable pretreatment of Fab' with mine-blocking reagents. Bioconjug. 7:1996;150-158.
13. Olsson P., Larm O. Biologically active heparin coated in medical devices. Int. J. Artif. Organs. 14:1991;453-456.
14. Somack R., Saifer M.G., Williams L.D. Preparation of long-acting superoxide dismutase using high molecular weight polyethylene glycol (41,000-72,000 daltons). Free Radic. Res. Commun. 2:1991;553-562.
15. Tregonning G.D., Transfeldt E.E., McCulloch J.A., MacNab I., Nachemson A. Chymopapain versus conventional surgery for lumbar disc herniation. Ten year results of treatment. J. Bone Joint Surg. Br. 73:1991;481-486.
16. Yang V.C., Linhardt R., Bernstein H., Cooney C.L., Langer R. Purification and characterization of heparinase from flavobaterium heparinum. J. Biol. Chem. 260:1985;1849-1857.
17. Yang V.C., Bernstein H., Langer R. An investigation of heparinase immobilization. Appl. Biochem. Biotech. 16:1988;129-143.
18. Yun J.H., Ma S.C., Fu B., Yang V.C., Meyerhoff M.E. Direct potentiometric membrane electrode measurements of heparin binding to macromolecules. Electroanalysis. 5:1993;719-724.
19. Yun J.H., Meyerhoff M.E., Yang V.C. Protamine sensitive polymer membrane electrode: characterization and bioanalytical applications. Anal. Biochem. 224:1995;212-220.